This document serves as a formal correction (Erratum) for a previously published study in the Annals of Surgical Oncology. While an erratum is not a new research paper, it is a critical component of the scientific record, ensuring that clinical outcomes and statistical data are accurately reported for the medical community.
The Study Context: In-Transit Melanoma
The original research (DOI: 10.1245/S10434-014-4199-Z) investigated the effectiveness of intralesional Interleukin-2 (IL-2) therapy. This treatment involves injecting IL-2 directly into melanoma lesions in patients with "in-transit disease." This specific stage of melanoma occurs when the cancer has spread through the lymphatic system but has not yet reached distant organs.
In such cases, achieving a Pathologic Complete Response (pCR)—the total disappearance of all invasive cancer cells in tissue samples—is a primary goal, as it is often a strong predictor of improved overall survival.
Corrected Clinical Outcomes
The purpose of this erratum is to rectify reporting errors found in the "Results" section of the original abstract. Accurate statistics are vital in oncology to inform clinical expectations and the design of future immunotherapy trials.
The study evaluated a cohort of 31 patients. The corrected distribution of patient outcomes is as follows:
- Pathologic Complete Response (pCR): 10 patients (32.3%)
- Partial Response: 17 patients (54.8%)
- Progressive Disease: 4 patients (12.9%)
Key Insights
The core significance of this correction lies in the clarification of the treatment's success rate. When combining complete and partial responses, the vast majority of the cohort—approximately 87.1%—saw a clinical benefit from the intralesional IL-2 therapy.
Furthermore, the confirmation that nearly one in three patients (32.3%) reached a pathologic complete response is a significant finding. Given that the original study links pCR to improved survival, these corrected figures provide a more precise benchmark for the efficacy of IL-2 in treating in-transit melanoma.
Conclusion
While the majority of patients in this cohort responded positively to the therapy, the data also highlights that a small subset (nearly 13%) experienced disease progression despite treatment. This erratum ensures that the medical literature accurately reflects these nuances, providing a reliable foundation for clinicians and researchers working with intralesional immunotherapies.
Summary updated